ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam Sells 7,414 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) COO Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock in a transaction on Monday, April 15th. The stock was sold at an average price of $66.33, for a total transaction of $491,770.62. Following the transaction, the chief operating officer now directly owns 825,206 shares of the company’s stock, valued at approximately $54,735,913.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Muthusamy Shanmugam also recently made the following trade(s):

• On Wednesday, April 17th, Muthusamy Shanmugam sold 9,520 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.40, for a total transaction of $622,608.00.
• On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total transaction of $1,000,889.75.
• On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total transaction of $659,577.55.
• On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.95, for a total transaction of $318,467.40.
• On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total transaction of $541,055.20.

ANI Pharmaceuticals Stock Down 0.1 %

Shares of NASDAQ ANIP opened at $65.48 on Thursday. The stock has a market capitalization of $1.38 billion, a P/E ratio of 77.95 and a beta of 0.79. The company has a 50-day moving average price of $64.60 and a 200-day moving average price of $58.52. ANI Pharmaceuticals, Inc. has a 1 year low of $36.99 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.57 and a quick ratio of 2.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The firm had revenue of $131.65 million during the quarter, compared to analysts’ expectations of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. New York State Teachers Retirement System boosted its holdings in ANI Pharmaceuticals by 0.9% during the third quarter. New York State Teachers Retirement System now owns 22,180 shares of the specialty pharmaceutical company’s stock worth $1,288,000 after purchasing an additional 200 shares during the last quarter. Teachers Retirement System of The State of Kentucky boosted its holdings in ANI Pharmaceuticals by 5.4% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 3,881 shares of the specialty pharmaceutical company’s stock worth $209,000 after purchasing an additional 200 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in ANI Pharmaceuticals by 4.3% during the third quarter. The Manufacturers Life Insurance Company now owns 5,435 shares of the specialty pharmaceutical company’s stock worth $316,000 after purchasing an additional 225 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in ANI Pharmaceuticals by 93.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 248 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in ANI Pharmaceuticals by 60.0% during the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 291 shares during the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on ANIP shares. Capital One Financial started coverage on shares of ANI Pharmaceuticals in a report on Friday, March 15th. They issued an “overweight” rating and a $80.00 price target for the company. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Truist Financial raised their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, HC Wainwright lifted their price objective on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $80.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.